

Simone Fulda

Publications 2008-2018

(last updated April 2018)

Faqar-Uz-Zaman SF, Heinicke U, Meister M, Vogler M, **Fulda S** (2018) BCL-x_L-selective BH₃ mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. **Cancer Lett** 412:131-142. <http://dx.doi.org/10.1016/j.canlet.2017.09.025>

Fulda S (2018) Cell death-based treatment of glioblastoma. **Cell Death Dis** 9:121. <http://dx.doi.org/10.1038/s41419-017-0021-8>

Fulda S (2018) Repurposing anticancer drugs for targeting necroptosis. **Cell Cycle**:1-8. <http://dx.doi.org/10.1080/15384101.2018.1442626>

Fulda S (2018) Targeting autophagy for the treatment of cancer. **Biol Chem**:published online 1 March 2018. <http://dx.doi.org/10.1515/hsz-2018-0105>

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, et al. (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. **Cell Death Differ**: published online 25 January 2018. <http://dx.doi.org/10.1038/s41418-017-0012-4>

Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, **Fulda S**, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM (2018) The landscape of genomic alterations across childhood cancers. **Nature**: published online 28 February 2018. <http://dx.doi.org/10.1038/nature25480>

Hussain M, Zimmermann V, van Wijk SJL, **Fulda S** (2018) Mouse lung fibroblasts are highly susceptible to necroptosis in a reactive oxygen species-dependent manner. **Biochem Pharmacol**:published online 11 January 2018. <http://dx.doi.org/10.1016/j.bcp.2018.01.025>

Kleinesudeik L, Rohde K, **Fulda S** (2018) Regulation of the antiapoptotic protein cFLIP by the glucocorticoid Dexamethasone in ALL cells. **Oncotarget** 9:16521-16532. <http://dx.doi.org/10.18632/oncotarget.24782>

Schmidt N, Haydn T, Schneider I, Busch H, Boerries M, **Fulda S** (2018) Smac mimetic induces an early wave of gene expression via NF-kappaB and AP-1 and a second wave via TNFR1 signaling. **Cancer Lett**:published online 5 February 2018. <http://dx.doi.org/10.1016/j.canlet.2018.01.082>

Amstein L, Ackermann J, Scheidel J, **Fulda S**, Dikic I, Koch I (2017) Manatee invariants reveal functional pathways in signaling networks. **BMC Syst Biol** 11:72. <http://dx.doi.org/10.1186/s12918-017-0448-7>

Bhatti IA, Abhari BA, **Fulda S** (2017) Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells. **Cancer Lett** 405:63-72. <http://dx.doi.org/10.1016/j.canlet.2017.07.008>

Cekay MJ, Roesler S, Frank T, Knuth AK, Eckhardt I, **Fulda S** (2017) Smac mimetics and type II interferon synergistically induce necroptosis in various cancer cell lines. **Cancer Lett** 410:228-237. <http://dx.doi.org/10.1016/j.canlet.2017.09.002>

Dolgikh N, **Fulda S** (2017) Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status. **Anti-Cancer Drugs** 28:1118-1125. <http://dx.doi.org/10.1097/cad.0000000000000552>

Feldmann F, Schenk B, Martens S, Vandenabeele P, **Fulda S** (2017) Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells. **Oncotarget** 8:68208-68220. <http://dx.doi.org/10.18632/oncotarget.19919>

Fulda S (2017) Autophagy in cancer therapy. **Front Oncol** 7:128. <http://dx.doi.org/10.3389/fonc.2017.00128>

Fulda S (2017) Therapeutic opportunities based on caspase modulation. **Semin Cell Dev Biol**:published online 15 December 2017. <http://dx.doi.org/10.1016/j.semcdb.2017.12.008>

Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, Choi AM, Chu CT, Codogno P, Colombo MI, Cuervo AM, Debnath J, Deretic V, Dikic I, Eskelinen EL, Fimia GM, **Fulda S**, Gewirtz DA, Green DR, Hansen M, Harper JW, Jaattela M, Johansen T, Juhasz G, Kimmelman AC, Kraft C, Ktistakis NT, Kumar S, Levine B, Lopez-Otin C, Madeo F, Martens S, Martinez J, Melendez A, Mizushima N, Munz C, Murphy LO, Penninger JM, Piacentini M, Reggiori F, Rubinsztein DC, Ryan KM, Santambrogio L, Scorrano L, Simon AK, Simon HU, Simonsen A, Tavernarakis N, Tooze SA, Yoshimori T, Yuan J, Yue Z, Zhong Q, Kroemer G (2017) Molecular definitions of autophagy and related processes. **EMBO J**:published online 19 June 2017. <http://dx.doi.org/10.15252/embj.201796697>

Habermann KJ, Grunewald L, van Wijk S, **Fulda S** (2017) Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death. **Cell Death Dis** 8:e3067. <http://dx.doi.org/10.1038/cddis.2017.412>

Haydn T, Metzger E, Schuele R, **Fulda S** (2017) Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells. **Cell Death Dis** 8:e2879. <http://dx.doi.org/10.1038/cddis.2017.239>

Martens S, Jeong M, Tonnus W, Feldmann F, Hofmans S, Goossens V, Takahashi N, Brasen JH, Lee EW, Van der Veken P, Joossens J, Augustyns K, **Fulda S**, Linkermann A, Song J, Vandenabeele P (2017) Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. **Cell Death Dis** 8:e2904. <http://dx.doi.org/10.1038/cddis.2017.298>

Merker M, Pfirrmann V, Oelsner S, **Fulda S**, Klingebiel T, Wels WS, Bader P, Rettinger E (2017) Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. **Oncotarget** 8:66137-66153. <http://dx.doi.org/10.18632/oncotarget.19821>

Probst L, Dachert J, Schenk B, **Fulda S** (2017) Lipoygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death. **Biochem Pharmacol** 140:41-52. <http://dx.doi.org/10.1016/j.bcp.2017.06.112>

Rohde K, Kleinesudeik L, Roesler S, Löwe O, Heidler J, Schröder K, Wittig I, Dröse S, **Fulda S** (2017) A Bak-dependent mitochondrial amplification step contributes to Smac mimetic/glucocorticoid-induced necroptosis. **Cell Death Differ** 24:83-97. <http://dx.doi.org/10.1038/cdd.2016.102>

Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kurner A, Haas J, Greve G, Haydn T, **Fulda S**, Lubbert M, Ludeke S, Berg T, Sippl W, Schule R, Jung M (2017) Structure-activity studies on N-Substituted tranlylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. **Eur J Med Chem** 144:52-67. <http://dx.doi.org/10.1016/j.ejmech.2017.12.001>

Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, **Fulda S**, Gascon S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. **Cell** 171:273-285. <http://dx.doi.org/10.1016/j.cell.2017.09.021>

Taeubner J, Brozou T, Qin N, Bartl J, Ginzel S, Schaper J, Felsberg J, **Fulda S**, Vokuhl C, Borkhardt A, Kuhlen M (2017) Congenital embryonal rhabdomyosarcoma caused by heterozygous concomitant PTCH1 and PTCH2 germline mutations. *Eur J Hum Genet* 26:137–142. <http://dx.doi.org/10.1038/s41431-017-0048-4>

Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, Kopp-Schneider A, Heinicke U, **Fulda S**, Witt O, Eggert A, Fischer M, Deubzer HE (2017) Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. *Cell Death Dis* 8:e2635. <http://dx.doi.org/10.1038/cddis.2017.49>

van Wijk SJL, Fricke F, Herhaus L, Gupta J, Hötte K, Pampaloni F, Grumati P, Kaulich M, Sou Y-s, Komatsu M, Greten FR, **Fulda S**, Heilemann M, Dikic I (2017) Linear ubiquitination of cytosolic *Salmonella* Typhimurium activates NF- κ B and restricts bacterial proliferation. *Nat Microbiol* 2:17066. <http://dx.doi.org/10.1038/nmicrobiol.2017.66>

Weiß LM, Hugle M, **Fulda S** (2017) Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. *Oncotarget* 8:52445-52456. <http://dx.doi.org/10.18632/oncotarget.17190>

Weiss LM, Hugle M, **Fulda S** (2017) Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. *Oncotarget* 8:52445-52456. <http://dx.doi.org/10.18632/oncotarget.17190>

Aredia F, Czaplinski S, **Fulda S**, Scovassi AI (2016) Molecular features of the cytotoxicity of an NHE inhibitor: Evidence of mitochondrial alterations, ROS overproduction and DNA damage. *BMC Cancer* 16:ArticleNr. 851. <http://dx.doi.org/10.1186/s12885-016-2878-9>

Chiocchetti AG, Haslinger D, Stein JL, de la Torre-Ubieta L, Cocchi E, Rothamel T, Lindlar S, Waltes R, **Fulda S**, Geschwind DH, Freitag CM (2016) Transcriptomic signatures of neuronal differentiation and their association with risk genes for autism spectrum and related neuropsychiatric disorders. *Transl Psychiatr* 6:ArticleNr. e864. <http://dx.doi.org/10.1038/tp.2016.119>

Czaplinski S, Hugle M, Stiehl V, **Fulda S** (2016) Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. *Oncotarget* 7:8700-8711.

Dachert J, Schoeneberger H, Rohde K, **Fulda S** (2016) RSL3 and Erastin differentially regulate redox signaling to promote Smac mimetic-induced cell death. *Oncotarget* 7:63779-63792. <http://dx.doi.org/10.18632/oncotarget.11687>

Engel K, Rudelius M, Slawska J, Jacobs L, Abhari BA, Altmann B, Kurutz J, Rathakrishnan A, Fernandez-Saiz V, Brunner A, Targosz BS, Loevecke F, Gloeckner CJ, Ueffing M, **Fulda S**, Pfreundschuh M, Trumper L, Klapper W, Keller U, Jost PJ, Rosenwald A, Peschel C, Bassermann F (2016) USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. *EMBO Mol Med* 8:851-862. <http://dx.doi.org/10.15252/emmm.201506047>

Fulda S (2016) Mitochondria, redox signaling and cell death in cancer. *Biol Chem* 397:583-583. <http://dx.doi.org/10.1515/hsz-2016-0199>

Gerges S, Rohde K, **Fulda S** (2016) Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells. *Cancer Lett* 375:127-132. <http://dx.doi.org/10.1016/j.canlet.2016.02.040>

Grunewald TGP, **Fulda S** (2016) Editorial: Biology-driven targeted therapy of pediatric soft-tissue and bone tumors: current opportunities and future challenges. *Front Oncol* 6:3. <http://dx.doi.org/10.3389/fonc.2016.00039>

Hannes S, Abhari BA, **Fulda S** (2016) Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked. *Cancer Lett* 380:31-38. <http://dx.doi.org/10.1016/j.canlet.2016.05.036>

Hass C, Belz K, Schoeneberger H, **Fulda S** (2016) Sensitization of acute lymphoblastic leukemia cells for LCL161-induced cell death by targeting redox homeostasis. *Biochem Pharmacol* 105:14-22. <http://dx.doi.org/10.1016/j.bcp.2016.01.004>

Heinicke U, Kupka J, Fichter I, **Fulda S** (2016) Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma. *Oncogene* 35:3729-3741. <http://dx.doi.org/10.1038/onc.2015.440>

Jennewein L, Ronellenfisch MW, Antonietti P, Ilina EI, Jung J, Stadel D, Flohr LM, Zinke J, von Renesse J, Drott U, Baumgarten P, Braczynski AK, Penski C, Burger MC, Theurillat JP, Steinbach JP, Plate KH, Dikic I, **Fulda S**, Brandts C, Kogel D, Behrends C, Harter PN, Mittelbronn M (2016) Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas. *Oncotarget* 7:20016-20032. <http://dx.doi.org/10.18632/oncotarget.7910>

Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 12:1-222. <http://dx.doi.org/10.1080/15548627.2015.1100356>

Lange M, Abhari BA, Hinrichs TM, **Fulda S**, Liese J (2016) Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells. *Biochem Pharmacol* 118:9-17. <http://dx.doi.org/10.1016/j.bcp.2016.08.011>

Lueck SC, Russ AC, Botzenhardt U, Schlenk RF, Zobel K, Deshayes K, Vucic D, Dohner H, Dohner K, **Fulda S**, Bullinger L (2016) Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. *Oncotarget* 7:49539-49551. <http://dx.doi.org/10.18632/oncotarget.10390>

Meister MT, Boedicker C, Graab U, Hugle M, Hahn H, Klingebiel T, **Fulda S** (2016) Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs. *Cancer Lett* 381:287-295. <http://dx.doi.org/10.1016/j.canlet.2016.07.007>

Reiter M, Eckhardt I, Haferkamp A, **Fulda S** (2016) Smac mimetic sensitizes renal cell carcinoma cells to interferon-alpha-induced apoptosis. *Cancer Lett* 375:1-8. <http://dx.doi.org/10.1016/j.canlet.2016.02.019>

Roesler S, Eckhardt I, Wolf S, **Fulda S** (2016) Cooperative TRAIL production mediates IFN α /Smac mimetic-induced cell death in TNF alpha-resistant solid cancer cells. *Oncotarget* 7:3709-3725.

Roos J, Grosch S, Werz O, Schroder P, Ziegler S, **Fulda S**, Paulus P, Urbschat A, Kuhn B, Maucher I, Fettel J, Vorup-Jensen T, Piesche M, Matrone C, Steinhilber D, Parnham MJ, Maier TJ (2016) Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells? *Pharmacol Ther* 157:43-64. <http://dx.doi.org/10.1016/j.pharmthera.2015.11.001>

Safferthal C, Rohde K, **Fulda S** (2016) Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells. *Oncogene* 36:1487-1502. <http://dx.doi.org/10.1038/onc.2016.310>

Seyfrid M, Marschall V, **Fulda S** (2016) Reactive oxygen species contribute toward Smac mimetic/temozolomide-induced cell death in glioblastoma cells. *Anti-Cancer Drugs* 27:953-959. <http://dx.doi.org/10.1097/cad.0000000000000412>

Weiss LM, Hugle M, Romero S, **Fulda S** (2016) Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells. *Int J Cancer* 138:497-506. <http://dx.doi.org/10.1002/ijc.29725>

Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jurgens H, Kramm CM, von Bueren AO, Westermann F, Fischer M, Burkhardt B, Wossmann W, Nathrath M, Bielack SS, Fruhwald MC, **Fulda S**, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B,

von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DTW, Witt O (2016) Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. *Eur J Cancer* 65:91-101. <http://dx.doi.org/10.1016/j.ejca.2016.06.009>

Chiocchetti AG, Kopp M, Waltes R, Haslinger D, Duketis E, Jarczok TA, Poustka F, Voran A, Graab U, Meyer J, Klauck SM, **Fulda S**, Freitag CM (2015) Variants of the CNTNAP2 5' promoter as risk factors for autism spectrum disorders: a genetic and functional approach. *Mol Psychiatr* 20:839-849. <http://dx.doi.org/10.1038/mp.2014.103>

Cristofanon S, Abhari BA, Krueger M, Tchoghandjian A, Momma S, Calaminus C, Vucic D, Pichler BJ, **Fulda S** (2015) Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis. *Cell Death Dis* 6:e1724. <http://dx.doi.org/10.1038/cddis.2014.592>

Czaplinski S, Abhari BA, Torkov A, Seggewiss D, Hugle M, **Fulda S** (2015) Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells. *Oncotarget* 6:41522-41534.

Engert F, Schneider C, Weiss LM, Probst M, **Fulda S** (2015) PARP inhibitors sensitize ewing sarcoma cells to temozolomide-induced apoptosis via the mitochondrial pathway. *Mol Cancer Ther* 14:2818-2830. <http://dx.doi.org/10.1158/1535-7163.mct-15-0587>

Fulda S (2015) Biomarker of sensitivity to PR-104 in leukemia. *Blood* 126:1153-1154. <http://dx.doi.org/10.1182/blood-2015-07-655225>

Fulda S (2015) Promises and challenges of smac mimetics as cancer therapeutics. *Clin Cancer Res* 21:5030-5036. <http://dx.doi.org/10.1158/1078-0432.ccr-15-0365>

Fulda S (2015) Safety and tolerability of TRAIL receptor agonists in cancer treatment. *Eur J Clin Pharmacol* 71:525-527. <http://dx.doi.org/10.1007/s00228-015-1823-1>

Fulda S (2015) Smac mimetics as IAP antagonists. *Semin Cell Dev Biol* 39:132-138. <http://dx.doi.org/10.1016/j.semcdb.2014.12.005>

Fulda S (2015) Targeting apoptosis for anticancer therapy. *Semin Cancer Biol* 31:84-88. <http://dx.doi.org/10.1016/j.semcancer.2014.05.002>

Fulda S (2015) Targeting extrinsic apoptosis in cancer: Challenges and opportunities. *Semin Cell Dev Biol* 39:20-25. <http://dx.doi.org/10.1016/j.semcdb.2015.01.006>

Fulda S (2015) Targeting IAP proteins in combination with radiotherapy. *Radiat Oncol* 10:DOI: 10.1186/s13014-015-0399-3. <http://dx.doi.org/10510.1186/s13014-015-0399-3>

Fulda S, Kogel D (2015) Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. *Oncogene* 34:5105-5113. <http://dx.doi.org/10.1038/onc.2014.458>

Gajer JM, Furdas SD, Grunder A, Gothwal M, Heinicke U, Keller K, Colland F, **Fulda S**, Pahl H, Fichtner I, Sippl W, Jung M (2015) Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. *Oncogenesis* 4:DOI: 10.1038/oncsis.2014.51. <http://dx.doi.org/e13710.1038/oncsis.2014.51>

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, et al. (2015) Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death Differ* 22:58-73. <http://dx.doi.org/10.1038/cdd.2014.137>

Graab U, Hahn H, **Fulda S** (2015) Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. *Oncotarget* 6:8722-8735.

Hehlgans S, Oppermann J, Reichert S, **Fulda S**, Rodel C, Rodel F (2015) The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. *Radiat Oncol* 10:Article Number: 198 <http://dx.doi.org/19810.1186/s13014-015-0507-4>

Heinicke U, Kupka J, **Fulda S** (2015) JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis. **Oncotarget** 6:37836-37851.

Hugle M, Belz K, **Fulda S** (2015) Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. **Cell Death Differ** 22:1946-1956. <http://dx.doi.org/10.1038/cdd.2015.59>

Hugle M, **Fulda S** (2015) Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma. **Cancer Lett** 360:1-9. <http://dx.doi.org/10.1016/j.canlet.2014.12.016>

Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M, Krieg A, Andreou D, Tunn PU, Durr HR, Rechl H, Schaser KD, Melcher I, Burdach S, Kulozik A, Specht K, Heinemann K, **Fulda S**, Bielack S, Jundt G, Tomlinson I, Korbel JO, Nathrath M, Baumhoer D (2015) Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. **Nat Commun** 6:Article Number: 8940 <http://dx.doi.org/8940> 10.1038/ncomms9940

Liese J, Abhari BA, **Fulda S** (2015) Smac mimetic and oleanolic acid synergize to induce cell death in human hepatocellular carcinoma cells. **Cancer Lett** 365:47-56. <http://dx.doi.org/10.1016/j.canlet.2015.04.018>

Lindemann C, Marschall V, Weigert A, Klingebiel T, **Fulda S** (2015) Smac mimetic-induced upregulation of CCL2/MCP-1 triggers migration and invasion of glioblastoma cells and influences the tumor microenvironment in a paracrine manner. **Neoplasia** 17:481-489. <http://dx.doi.org/10.1016/j.neo.2015.05.002>

Marschall V, **Fulda S** (2015) Smac mimetic-induced upregulation of interferon-beta sensitizes glioblastoma to temozolomide-induced cell death. **Cell Death Dis** 6:e1888. <http://dx.doi.org/e1888> 10.1038/cddis.2015.235

Michaelis M, Agha B, Rothweiler F, Loschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter PN, Abhari BA, **Fulda S**, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks WG, Zehner R, Cinatl J, Wass MN (2015) Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. **Sci Rep** 5:DOI: 10.1038/srep08202. <http://dx.doi.org/8202> 10.1038/srep08202

Nonnenmacher L, Westhoff MA, **Fulda S**, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S, Debatin KM (2015) RIST: A potent new combination therapy for glioblastoma. **Int J Cancer** 136:E173-E187. <http://dx.doi.org/10.1002/ijc.29138>

Opel D, Schnaiter A, Dodier D, Jovanovic M, Gerhardinger A, Idler I, Mertens D, Bullinger L, Stilgenbauer S, **Fulda S** (2015) Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. **Int J Cancer** 137:2959-2970. <http://dx.doi.org/10.1002/ijc.29650>

Rapino F, Abhari BA, Jung M, **Fulda S** (2015) NIK is required for NF-kappa B-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways. **Cell Death Dis** 6:DOI: 10.1038/cddis.2014.584. <http://dx.doi.org/e1692> 10.1038/cddis.2014.584

Ridzewski R, Rettberg D, Dittmann K, Cuvelier N, **Fulda S**, Hahn H (2015) Hedgehog inhibitors in rhabdomyosarcoma: a comparison of four compounds and responsiveness of four cell lines. **Front Oncol** 5. <http://dx.doi.org/130> 10.3389/fonc.2015.00130

Schenk B, **Fulda S** (2015) Reactive oxygen species regulate Smac mimetic/TNF alpha-induced necroptotic signaling and cell death. **Oncogene** 34:5796-5806. <http://dx.doi.org/10.1038/onc.2015.35>

Schoeneberger H, Belz K, Schenk B, **Fulda S** (2015) Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death. **Oncogene** 34:4032-4043. <http://dx.doi.org/10.1038/onc.2014.338>

Schott C, Graab U, Cuvelier N, Hahn H, **Fulda S** (2015) Oncogenic RAS mutants confer resistance of RMS13 rhabdomyosarcoma cells to oxidative stress-induced ferroptotic cell death. *Front Oncol* 5:Article Number: 131 <http://dx.doi.org/10.3389/fonc.2015.00131>

Stehle A, Hugle M, **Fulda S** (2015) Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. *Cancer Lett* 365:37-46. <http://dx.doi.org/10.1016/j.canlet.2015.04.011>

Steinwascher S, Nagues AL, Schoeneberger H, **Fulda S** (2015) Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. *Cancer Lett* 366:32-43. <http://dx.doi.org/10.1016/j.canlet.2015.05.020>

Unland R, Clemens D, Heinicke U, Potratz JC, Hotfilder M, **Fulda S**, Wardelmann E, Fruhwald MC, Dirksen U (2015) Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines. *Anti-Cancer Drugs* 26:843-851. <http://dx.doi.org/10.1097/cad.0000000000000256>

Bake V, Roesler S, Eckhardt I, Belz K, **Fulda S** (2014) Synergistic interaction of Smac mimetic and IFN alpha to trigger apoptosis in acute myeloid leukemia cells. *Cancer Lett* 355:224-231. <http://dx.doi.org/10.1016/j.canlet.2014.08.040>

Belz K, Schoeneberger H, Wehner S, Weigert A, Bonig H, Klingebiel T, Fichtner I, **Fulda S** (2014) Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. *Blood* 124:240-250. <http://dx.doi.org/10.1182/blood-2013-05-500918> [blood-2013-05-500918 \[pii\]](http://dx.doi.org/10.1182/blood-2013-05-500918)

Braig S, Bischoff F, Abhari BA, Meijer L, **Fulda S**, Skaltsounis L, Vollmar AM (2014) The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer. *Biochem Pharmacol* 91:157-167. <http://dx.doi.org/10.1016/j.bcp.2014.07.009>

Braig S, Wiedmann RM, Liebl J, Singer M, Kubisch R, Schreiner L, Abhari BA, Wagner E, Kazmaier U, **Fulda S**, Vollmar AM (2014) Pretubulysin: a new option for the treatment of metastatic cancer. *Cell Death Dis* 5:e1001. <http://dx.doi.org/10.1038/cddis.2013.510>

Chromik J, Safferthal C, Serve H, **Fulda S** (2014) Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. *Cancer Lett* 344:101-109. <http://dx.doi.org/10.1016/j.canlet.2013.10.018>

Eckhardt I, Weigert A, **Fulda S** (2014) Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response. *Cell Death Dis* 5:e1562. <http://dx.doi.org/10.1038/cddis.2014.498>

Eirich J, Braig S, Schyschka L, Servatius P, Hoffmann J, Hecht S, **Fulda S**, Zahler S, Antes I, Kazmaier U, Sieber SA, Vollmar AM (2014) A small molecule inhibits protein disulfide isomerase and triggers the chemosensitization of cancer cells. *Angew Chem Int Edit* 53:12960-12965. <http://dx.doi.org/10.1002/anie.201406577>

Fischer S, Ronellenfitch MW, Thiebold AL, Harter PN, Reichert S, Kogel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, **Fulda S**, Bahr O (2014) Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. *PLOS ONE* 9:e94921. <http://dx.doi.org/10.1371/journal.pone.0094921>

Fulda S (2014) Molecular pathways: targeting inhibitor of apoptosis proteins in cancer-from molecular mechanism to therapeutic application. *Clin Cancer Res* 20:289-295. <http://dx.doi.org/10.1158/1078-0432.ccr-13-0227>

Fulda S (2014) Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. *Oncogene* 33:671-676. <http://dx.doi.org/10.1038/onc.2013.63>

- Fulda S** (2014) Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling. *Mitochondrion* 19:85-87. <http://dx.doi.org/10.1016/j.mito.2014.04.011>
- Fulda S** (2014) Targeting inhibitor of apoptosis proteins for cancer therapy: a double-edge sword? *J Clin Oncol* 32:3190-3191. <http://dx.doi.org/10.1200/jco.2014.56.8741>
- Fulda S** (2014) Therapeutic exploitation of necroptosis for cancer therapy. *Semin Cell Dev Biol* 35:51-56. <http://dx.doi.org/10.1016/j.semcdb.2014.07.002>
- Heinicke U, **Fulda S** (2014) Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA. *Cancer Lett* 351:50-58. <http://dx.doi.org/10.1016/j.canlet.2014.04.021>
- Jendrossek V, **Fulda S** (2014) Second EACR conference on cell death in cancer, Amsterdam, the Netherlands, 30 January-1 February 2014. *Cell Death Differ* 21:1180-1182. <http://dx.doi.org/10.1038/cdd.2014.51>
- Rapino F, Jung M, **Fulda S** (2014) BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways. *Oncogene* 33:1713-1724. <http://dx.doi.org/10.1038/onc.2013.110>
- Rettinger E, Glatthaar A, Ahangarian Abhari B, Oelsner S, Pfirrmann V, Huenecke S, Kuci S, Kreyenberg H, Willasch A, Klingebiel T, **Fulda S**, Bader P (2014) SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-induced killer (CIK) cells: a potential challenge for combination therapy. *Frontiers in Pediatrics* 2. <http://dx.doi.org/10.3389/fped.2014.00075>
- Tchoghandjian A, Jennewein C, Eckhardt I, Momma S, Figarella-Branger D, **Fulda S** (2014) Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF- κ B. *Cell Death Dis* 21:735-747. <http://dx.doi.org/10.1038/cdd.2013.200>
- Abhari BA, Cristofanon S, Kappler R, von Schweinitz D, Humphreys R, **Fulda S** (2013) RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex. *Oncogene* 32:3263-3273. <http://dx.doi.org/10.1038/Onc.2012.337>
- Basit F, Cristofanon S, **Fulda S** (2013) Obatoclox (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. *Cell Death Differ* 20:1161-1173. <http://dx.doi.org/10.1038/cdd.2013.45>
- Eckhardt I, Roesler S, **Fulda S** (2013) Identification of DR5 as a critical, NF-kappa B-regulated mediator of Smac-induced apoptosis. *Cell Death Dis* 4:e936. <http://dx.doi.org/10.1038/cddis.2013.457>
- Enzenmuller S, Gonzalez P, Debatin KM, **Fulda S** (2013) Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis. *Anti-Cancer Drug* 24:14-19. <http://dx.doi.org/10.1097/CAD.0b013e32835a36db>
- Enzenmüller S, Gonzalez P, Karpel-Massler G, Debatin KMI, **Fulda S** (2013) GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. *Cancer Lett* 329:27-36. <http://dx.doi.org/10.1016/j.canlet.2012.09.007>
- Fulda S** (2013) Alternative cell death pathways and cell metabolism. *Int J Cell Biol* 2013:463637. <http://dx.doi.org/10.1155/2013/463637>
- Fulda S** (2013) How to target apoptosis signaling pathways for the treatment of pediatric cancers. *Front Oncol* 3:22. <http://dx.doi.org/10.3389/fonc.2013.00022>
- Fulda S** (2013) Modulation of mitochondrial apoptosis by PI3K inhibitors. *Mitochondrion* 13:195-198. <http://dx.doi.org/10.1016/j.mito.2012.05.001>
- Fulda S** (2013) Molecular targeted therapies for rhabdomyosarcoma: Focus on Hedgehog and apoptosis signaling. *Klin Padiatr* 225:115-119. <http://dx.doi.org/10.1055/s-0032-1331762>

- Fulda S** (2013) Regulation of cell death in cancer - possible implications for immunotherapy. *Front Oncol* 3:29. <http://dx.doi.org/10.3389/fonc.2013.00029>
- Fulda S** (2013) Targeting apoptosis pathways in childhood malignancies. *Cancer Lett* 332:369-373. <http://dx.doi.org/10.1016/j.canlet.2010.10.003>
- Fulda S** (2013) Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer. *Expert Opin Ther Tar* 17:195-201. <http://dx.doi.org/10.1517/14728222.2013.736499>
- Guenther MK, Graab U, **Fulda S** (2013) Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. *Cancer Lett* 337:200-209. <http://dx.doi.org/10.1016/j.canlet.2013.05.010>
- Preuss E, Hugle M, Reimann R, Schlecht M, **Fulda S** (2013) Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. *J Biol Chem* 288:35287-35296. <http://dx.doi.org/10.1074/jbc.M113.495986>
- Rapino F, Naumann I, **Fulda S** (2013) Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. *Cell Death Dis* 4:e925. <http://dx.doi.org/10.1038/cddis.2013.440>
- Richter GHS, Fasan A, Hauer K, Grunewald TGP, Berns C, Rossler S, Naumann I, Staeger MS, **Fulda S**, Esposito I, Burdach S (2013) G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1. *J Pathol* 230:70-81. <http://dx.doi.org/10.1002/Path.4170>
- Schmid SJ, Glatzel MC, Welke C, Kornmann M, Kleger A, Barth TFE, **Fulda S**, Lennerz JK, Moller P (2013) Absence of FLICE-inhibitory protein is a novel independent prognostic marker for very short survival in pancreatic ductal adenocarcinoma. *Pancreas* 42:1114-1119.
- Seitz C, Hugle M, Cristofanon S, Tchoghandjian A, **Fulda S** (2013) The dual PI3K/mTOR inhibitor NVP-BE235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. *Int J Cancer* 132:2682-2693. <http://dx.doi.org/10.1002/ijc.27935>
- Steinhart L, Belz K, **Fulda S** (2013) Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. *Cell Death Dis* 4:e802. <http://dx.doi.org/10.1038/cddis.2013.320>
- Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K, **Fulda S** (2013) Identification of non-canonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. *Cell Death Dis* 4:e564. <http://dx.doi.org/10.1038/cddis.2013.70>
- Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, Vucic D, Debatin KM, **Fulda S** (2013) Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. *Oncogene* 32:988-997. <http://dx.doi.org/10.1038/onc.2012.108>
- Westhoff MA, Faham N, Marx D, Nonnenmacher L, Jennewein C, Enzenmuller S, Gonzalez P, **Fulda S**, Debatin KM (2013) Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma. *PLOS ONE* 8:e83128. <http://dx.doi.org/e83128>
10.1371/journal.pone.0083128
- Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Hacker S, Vellanki SHK, Lausen J, Debatin KM, **Fulda S** (2012) Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. *Oncogene* 31:4677-4688. <http://dx.doi.org/10.1038/onc.2011.614>
- Basit F, Humphreys R, **Fulda S** (2012) RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis. *J Biol Chem* 287:38767-38777. <http://dx.doi.org/10.1074/jbc.M112.398966>
- Behrends C, **Fulda S** (2012) Receptor proteins in selective autophagy. *Int J Cell Biol* 2012:article ID 673290, 9 pp, doi:10.1155/2012/673290.

Cristofanon S, **Fulda S** (2012) ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. *Cell Death Dis* 3:e432. <http://dx.doi.org/10.1038/cddis.2012.163>

Ehrhardt H, Hofig I, Wachter F, Obexer P, **Fulda S**, Terziyska N, Jeremias I (2012) NOXA as critical mediator for drug combinations in polychemotherapy. *Cell Death Dis* 3:e327. <http://dx.doi.org/e32710.1038/cddis.2012.53>

Fulda S (2012) Cell death pathways as therapeutic targets in rhabdomyosarcoma. *Sarcoma* 2012:326210.

Fulda S (2012) Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. *Leukemia* 26:1155-1165. <http://dx.doi.org/10.1038/leu.2012.4>

Fulda S (2012) Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. *Exp Cell Res* 318:1208-1212. <http://dx.doi.org/10.1016/j.yexcr.2012.02.005>

Fulda S (2012) Inhibitor of Apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. *Cancer Treat Rev* 38:760-766. <http://dx.doi.org/10.1016/j.ctrv.2012.01.005>

Fulda S (2012) Regulation of cell death and survival by resveratrol: implications for cancer therapy. *Anti-Cancer Agent Me* 12:874-879.

Fulda S (2012) Shifting the balance of mitochondrial apoptosis: therapeutic perspectives. *Frontiers in Oncology - Molecular and Cellular Oncology* 2:121. <http://dx.doi.org/10.3389/fonc.2012.00121>

Fulda S, Rajalingam K, Dikic I (2012) Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. *EMBO Mol Med* 4:545-556. <http://dx.doi.org/10.1002/emmm.201100707>

Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in cancer. *Nat Rev Drug Discov* 11:109-124. <http://dx.doi.org/10.1038/nrd3627>

Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, **Fulda S**, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nunez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. *Cell Death Differ* 19:107-120. <http://dx.doi.org/10.1038/cdd.2011.96>

Giaisi M, Kohler R, **Fulda S**, Krammer PH, Li-Weber M (2012) Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. *Int. J Cancer* 131:1003-1008. <http://dx.doi.org/10.1002/ijc.26458>

Gonzalez P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F, Debatin KM, **Fulda S** (2012) Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. *Cell Death Differ* 19:1337-1346. <http://dx.doi.org/10.1038/cdd.2012.10>

Huber-Lang M, Denk S, **Fulda S**, Eler E, Kalbitz M, Weckbach S, Schneider EM, Weiss M, Kanse SM, Perl M (2012) Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro. *Mol Immunol* 50:60-65. <http://dx.doi.org/10.1016/j.molimm.2011.12.005>

Jennewein C, Karl S, Baumann B, Micheau O, Debatin KM, **Fulda S** (2012) Identification of a novel pro-apoptotic role of NF-kappa B in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells. *Oncogene* 31:1468-1474. <http://dx.doi.org/10.1038/onc.2011.333>

Kovar H, Alonso J, Aman P, Aryee DNT, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, **Fulda S**, Helman LJ, Herrero-Martin D, Hogendoorn PCW, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GHS, Riedmann LT, Rossig C, Schafer BW, Schwentner R, Scotlandi K, Sorensen PH, Staeger MS,

Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R (2012) The first European interdisciplinary ewing sarcoma research summit. **Frontiers in Oncology - In Pediatric Oncology** 2:54.

Löder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, Bertrand MJM, Vandenabeele P, Jeremias I, Debatin KM, **Fulda S** (2012) RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. **Leukemia** 26:1020-1029. <http://dx.doi.org/10.1038/leu.2011.353>

Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, **Fulda S**, Bader P (2012) The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. **Cytotherapy** 14:91-103. <http://dx.doi.org/10.3109/14653249.2011.613931>

Rettinger E, Meyer V, Kreyenberg H, Volk A, Kuci S, Willasch A, Koscielniak E, **Fulda S**, Wels WS, Boenig H, Klingebiel T, Bader P (2012) Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. **Frontiers in Oncology - In Pediatric Oncology** 2:32.

Rodel F, Sprenger T, Kaina B, Liersch T, Rodel C, **Fulda S**, Hehlhans S (2012) Survivin as a prognostic/predictive marker and molecular target in cancer therapy. **Curr Med Chem** 19:3679-3688.

Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D, Debatin KM, **Fulda S** (2011) PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. **Oncogene** 30:494-503. <http://dx.doi.org/10.1038/onc.2010.429>

Haag C, Stadel D, Zhou SX, Bachem MG, Moller P, Debatin KM, **Fulda S** (2011) Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. **Gut** 60:225-237. <http://dx.doi.org/10.1136/gut.2009.202325>

Häcker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, Rutkowski S, Debatin KM, **Fulda S** (2011) Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. **Oncogene** 30:2275-2281. <http://dx.doi.org/10.1038/onc.2010.599>

Vanlangenakker N, Berghe TV, Bogaert P, Laukens B, Zobel K, Deshayes K, Vucic D, **Fulda S**, Vandenabeele P, Bertrand MJM (2011) cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. **Cell Death Differ** 18:656-665. <http://dx.doi.org/10.1038/cdd.2010.138>

Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, **Fulda S** (2010) Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. **Faseb J** 24:1997-2009. <http://dx.doi.org/10.1096/fj.09-142943>

Mohr A, Albarenque SM, Deedigan L, Yu R, Reidy M, **Fulda S**, Zwacka RM (2010) Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells. **Stem Cells** 28:2109-2120. <http://dx.doi.org/10.1002/stem.533>

Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM, **Fulda S** (2009) Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. **Blood** 113:1710-1722. <http://dx.doi.org/10.1182/blood-2007-09-114314>

Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H, Debatin KM, Stilgenbauer S, **Fulda S** (2009) A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. **Cancer Res** 69:8977-8986. <http://dx.doi.org/10.1158/0008-5472.can-09-2604>

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Moller P, Gschwend JE, Simmet T, Debatin KM, **Fulda S** (2009) Small molecule XIAP inhibitors enhance TRAIL-Induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. **Cancer Res** 69:2425-2434. <http://dx.doi.org/10.1158/0008-5472.can-08-2436>

Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, **Fulda S** (2008) Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. **Cancer Res** 68:6271-6280. <http://dx.doi.org/10.1158/0008-5472.can-07-6769>

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, **Fulda S** (2008) Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. **Cancer Res** 68:7956-7965. <http://dx.doi.org/10.1158/0008-5472.can-08-1296>